Summary
The l-arginine antagonist NG-monomethyl-l-arginine has been shown to inhibit nitric oxide formation from l-arginine in endothelial cells. In the present study NG-monomethyl-l-arginine was used to assess the role of l-arginine for cyclic GMP stimulation by vasopressin in a kidney epithelial cell line (LLC-PK1). Preincubation of cells with 1 μmol/l, 10 μmol/l and 100 μmol/l NG-monomethyl-l-arginine decreased cyclic GMP stimulation at 1 μmol/l vasopressin by 25%, 71% and 90%, respectively. This inhibition by NG-monomethyl-l-arginine was markedly reduced by l-arginine (2 mmol/1) but not d-arginine (2 mmol/1). Cyclic GMP stimulation by the calcium ionophore A23187 was also inhibited by NG-monomethyl-l-arginine and enantioselectively restored by l-arginine. However, NG-monomethyl-l-arginine did not affect cyclic GMP stimulation by sodium nitroprusside that spontaneously releases nitric oxide. These results suggest that, in kidney epithelial cells, vasopressin induces nitric oxide formation from l-arginine leading to activation of soluble guanylate cyclase. It is concluded that nitric oxide formation from l-arginine is not only responsible for endothelium-dependent relaxation but may be a more general pathway with regulatory function for intracellular guanylate cyclase activity.
References
Arnold WP, Mittal CK, Katsuki S, Murad F (1977) Nitric oxide activates guanylate cyclase and increases guanosine 3′:5′-cyclic monophosphate levels in various tissue preparations. Proc Natl Acad Sci USA 74:3203–3207.
Feelisch M, Noack EA (1987) Correlation between nitric oxide formation during degradation of organic nitrates and activation of guanylate cyclase. Eur J Pharmacol 139:19–30.
Förstermann U, Mülsch A, Böhme E, Busse R (1986) Stimulation of soluble guanylate cyclase by an acetylcholine-induced endothelium-derived factor from rabbit and canine arteries. Circ Res 58:531–538.
Gerzer R, Brash AR, Hardman JG (1986) Activation of soluble guanylate cyclase by arachidonic acid and 15-lipoxygenase products. Biochim Biophys Acta 886:383–389.
Jard S (1983) Vasopressin: mechanisms of receptor activation. Prog Brain Res 60:383–394.
Katusic ZS, Shepherd JT, Vanhoutte PM (1984) Vasopressin causes endothelium-dependent relaxations of the canine basilar artery. Circ Res 55:575–579.
Leitman DC, Agnost VL, Catalano RM, Schröder H, Waldman SA, Bennett BM, Tuan JJ, Murad F (1988) Atrial natriuretic peptide, oxytocin, and vasopressin increase guanosine 3′,5′-monophosphate in LLC-PK1 kidney epithelial cells. Endocrinology 122:1478–1485.
Lückhoff A (1988) Release of prostacyclin and EDRF from endothelial cells is differentially controlled by extra- and intracellular calcium. Eicosanoids 1:5–11.
Ogura A, Ozaki K, Kudo Y, Amano T (1986) Cytosolic calcium elevation and cGMP production induced by serotonin in a clonal cell of glial origin. J Neurosci 6:2489–2494.
Palmer RMJ, Moncada S (1989) A novel citrulline-forming enzyme implicated in the formation of nitric oxide by vascular endothelial cells. Biochem Biophys Res Commun 158:348–352.
Palmer RMJ, Ferrige AG, Moncada S (1987) Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327:524–526.
Palmer RMJ, Rees DD, Ashton DS, Moncada S (1988) l-arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochem Biophys Res Commun 153:1251–1256.
Roy C, Ausiello DA (1981) Characterization of (8-lysine) vasopressin binding sites on a pig kidney cell line (LLC-PK1). J Biol Chem 256:3415–3422.
Steiner AL, Parker CW, Kipnis DM (1972) Radioimmunoassay for cyclic nucleotides. J Biol Chem 247:1106–1113.
Waldman SA, Murad F (1987) Cyclic GMP synthesis and function. Pharmacol Rev 39:163–196.
Author information
Authors and Affiliations
Additional information
Send offprint requests to K. Schror at the above address
Rights and permissions
About this article
Cite this article
Schröder, H., Schror, K. Cyclic GMP stimulation by vasopressin in LLC-PK1 kidney epithelial cells is l-arginine-dependent. Naunyn-Schmiedeberg's Arch Pharmacol 340, 475–477 (1989). https://doi.org/10.1007/BF00167052
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00167052